Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Company Overview More
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company’s lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
CEO: McArthur Ph.D., James G.
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Futubull > Quotes > PEPG PepGen > Detailed Quotes

PEPG PepGen

Watchlist
10.300-0.050-0.48%
Close 05/26 20:00 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
10.850
Open
10.430
Turnover
414.89K
Low
10.240
Pre Close
10.350
Volume
39.65K
Market Cap
211.81M
P/E(TTM)
Loss
52wk High
16.990
Shares
20.56M
P/E(Static)
Loss
52wk Low
7.820
Float Cap
74.16M
Bid/Ask %
0.00%
Historical High
16.990
Shs Float
7.20M
Volume Ratio
0.38
Historical Low
7.820
Dividend TTM
--
Div Yield TTM
--
P/B
-6.60
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
0.55%
Amplitude
5.89%
Avg Price
10.464
Lot Size
1
Float Cap
74.16M
Bid/Ask %
0.00%
Historical High
16.990
Shs Float
7.20M
Volume Ratio
0.38
Historical Low
7.820
Dividend TTM
--
P/B
-6.60
Dividend LFY
--
Turnover Ratio
0.55%
Amplitude
5.89%
Avg Price
10.464
Lot Size
1
Price Forecast

No Data

News

Comment

Back to the Top